The 2026 Basic Cardiovascular Sciences Scientific Sessions (AHA-BCVS 2026) of the American Heart Association (AHA) will be held from July 13 to 16, 2026, in Boston, Massachusetts, USA. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.'s subsidiary, Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics"), will present preclinical research results on DR10624, a long-acting, first-in-class (FIC) tri-specific agonist targeting fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon-like peptide-1 receptor (GLP-1R), demonstrating its anti-atherosclerotic effects at the conference.
Atherosclerosis is the primary pathological basis of cardiovascular disease, and there remains a lack of effective treatments that intervene through multiple pathways. DR10624, as a novel triple agonist, has previously shown significant lipid-lowering and liver fat-reducing effects in clinical studies. This study further explores the therapeutic effects and mechanisms of DR10624 in an atherosclerosis model. In this study, an atherosclerosis model was established in ApoE knockout (KO) mice fed a high-fat diet. DR10624 was administered via subcutaneous injection, and the GLP-1R monoagonist semaglutide, which has demonstrated cardiovascular benefits, was used as a positive control. Results showed that DR10624 significantly reduced body weight, serum total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, and improved cardiovascular risk-related indicators such as non-high-density lipoprotein cholesterol (non-HDL-C).
In terms of vascular pathology, DR10624 treatment significantly reduced aortic lipid deposition and abnormal intra-plaque collagen accumulation, while improving hepatic lipid metabolism. Transcriptome sequencing analysis of the aorta revealed that as a multi-target agonist, DR10624 broadly regulates multiple pathways associated with atherosclerosis pathogenesis, including inflammatory signaling, cholesterol metabolism, and extracellular matrix remodeling. Compared to semaglutide, DR10624 showed more comprehensive regulatory effects and broader pathway coverage. These findings provide scientific evidence supporting the potential of DR10624 to offer integrated benefits beyond traditional lipid-lowering and weight reduction in the treatment of atherosclerosis.
The study results indicate that DR10624 not only regulates blood lipids, reduces body weight, and improves hepatic lipid metabolism, but also acts directly on the vessel wall to significantly reduce plaque burden and improve plaque stability. Its consistent and superior performance over semaglutide on multiple key endpoints highlights the clinical translational potential of DR10624 as a comprehensive therapeutic strategy for atherosclerosis.
Conference Information
-
Conference Name: 2026 Basic Cardiovascular Sciences Scientific Sessions
-
Conference Dates: July 13–16, 2026
-
Conference Location: Boston, Massachusetts, USA
-
Presentation Format: Poster Presentation
-
Abstract Number: 4530326
-
Abstract Title: DR10624, a Novel Triple Agonist, Exhibits Superior Anti-Atherosclerotic Effects and Promising Potential for Clinical Translation
-
Conference Introduction: BCVS is a world-leading academic conference on basic cardiovascular and translational research organized by the American Heart Association. It serves as one of the most important international platforms for scientific exchange in cardiovascular disease research. The annual meeting aims to improve fundamental vascular regulatory mechanisms by exploring novel therapies for cardiovascular disease and advancing research in areas such as microRNA, cardiac gene and cell therapy, cardiac development, and tissue engineering.
Doer Biologics will continue to dedicate itself to innovative drug development in the cardiometabolic field, advancing potential "best-in-class" therapies such as DR10624 toward clinical translation, and providing patients with more comprehensive and effective treatment options.